As with EGFR mutations in advanced NSCLC and PIK3CA mutations in advanced breast cancer, strong concordance has been found between the RAS mutational status of CRC tissue and matching plasma in patients with advanced CRC [62,64,65,66]. The gene discussed is EGFR; the disease is breast cancer.